"Apolipoprotein E4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A major and the second most common isoform of apolipoprotein E. In humans, Apo E4 differs from APOLIPOPROTEIN E3 at only one residue 112 (cysteine is replaced by arginine), and exhibits a lower resistance to denaturation and greater propensity to form folded intermediates. Apo E4 is a risk factor for ALZHEIMER DISEASE and CARDIOVASCULAR DISEASES.
| Descriptor ID |
D053327
|
| MeSH Number(s) |
D10.532.091.500.750 D12.776.070.400.500.750 D12.776.521.120.500.750
|
| Concept/Terms |
Apolipoprotein E4- Apolipoprotein E4
- Apolipoprotein E-4
- Apolipoprotein E 4
- Apo E4
- ApoE4
- Apo E epsilon 4
- Apo E-4
- Apo E 4
|
Below are MeSH descriptors whose meaning is more general than "Apolipoprotein E4".
Below are MeSH descriptors whose meaning is more specific than "Apolipoprotein E4".
This graph shows the total number of publications written about "Apolipoprotein E4" by people in this website by year, and whether "Apolipoprotein E4" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 5 | 5 |
| 1996 | 0 | 7 | 7 |
| 1997 | 0 | 8 | 8 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 15 | 15 |
| 2000 | 0 | 13 | 13 |
| 2001 | 0 | 8 | 8 |
| 2002 | 0 | 12 | 12 |
| 2003 | 0 | 8 | 8 |
| 2004 | 0 | 10 | 10 |
| 2005 | 0 | 15 | 15 |
| 2006 | 0 | 12 | 12 |
| 2007 | 11 | 2 | 13 |
| 2008 | 18 | 9 | 27 |
| 2009 | 12 | 9 | 21 |
| 2010 | 19 | 12 | 31 |
| 2011 | 13 | 10 | 23 |
| 2012 | 17 | 14 | 31 |
| 2013 | 23 | 10 | 33 |
| 2014 | 18 | 16 | 34 |
| 2015 | 13 | 10 | 23 |
| 2016 | 22 | 7 | 29 |
| 2017 | 15 | 19 | 34 |
| 2018 | 17 | 6 | 23 |
| 2019 | 19 | 12 | 31 |
| 2020 | 14 | 19 | 33 |
| 2021 | 9 | 17 | 26 |
| 2022 | 17 | 26 | 43 |
| 2023 | 14 | 24 | 38 |
| 2024 | 17 | 17 | 34 |
| 2025 | 3 | 1 | 4 |
Below are the most recent publications written about "Apolipoprotein E4" by people in Profiles.
-
Interaction between APOE Ɛ4 status, chemotherapy and endocrine therapy on cognitive functioning among breast cancer survivors: the CANTO-Cog longitudinal study. Breast Cancer Res. 2025 Feb 19; 27(1):25.
-
Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD. Mol Neurodegener. 2025 Feb 04; 20(1):15.
-
Suppressing APOE4-induced neural pathologies by targeting the VHL-HIF axis. Proc Natl Acad Sci U S A. 2025 Feb 04; 122(5):e2417515122.
-
Relationships Between APOE, Type 2 Diabetes, and Cardiovascular Disease in Postmenopausal Women. J Gerontol A Biol Sci Med Sci. 2025 Jan 16; 80(2).
-
Sex and APOE ε4 allele differences in longitudinal white matter microstructure in multiple cohorts of aging and Alzheimer's disease. Alzheimers Dement. 2025 Jan; 21(1):e14343.
-
Curation and validation of electronic medical record-based dementia diagnoses in the VA Million Veteran Program. J Alzheimers Dis. 2025 Jan; 103(1):180-193.
-
Connectivity, Pathology, and ApoE4 Interactions Predict Longitudinal Tau Spatial Progression and Memory. Hum Brain Mapp. 2024 Dec 01; 45(17):e70083.
-
Clinical Manifestations. Alzheimers Dement. 2024 Dec; 20 Suppl 3:e090079.
-
Tlr7 drives sex differences in age- and Alzheimer's disease-related demyelination. Science. 2024 Nov 29; 386(6725):eadk7844.
-
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience. Mol Neurodegener. 2024 Oct 31; 19(1):81.